KBC Group’s TG Therapeutics TGTX Stock Holding History

KBC Group’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$177K	Buy	5,335 +1,195	+29%	+$35.6K	﹤0.01%	1022
2025 Q4	$123K	Hold	4,140	–	–	﹤0.01%	1155
2025 Q3	$150K	Hold	4,140	–	–	﹤0.01%	1034
2025 Q2	$149K	Sell	4,140 -2,887	-41%	-$107K	﹤0.01%	989
2025 Q1	$277K	Buy	7,027 +67	+1%	+$2.25K	﹤0.01%	904
2024 Q4	$209K	Buy	6,960 +2,285	+49%	+$65.6K	﹤0.01%	1103
2024 Q3	$109K	Buy	4,675 +1,092	+30%	+$23.8K	﹤0.01%	1236
2024 Q2	$64K	Buy	3,583 +437	+14%	+$6.97K	﹤0.01%	1468
2024 Q1	$48K	Hold	3,146	–	–	﹤0.01%	1586
2023 Q4	$54K	Hold	3,146	–	–	﹤0.01%	1475
2023 Q3	$26K	Buy	+3,146	New	+$43.9K	﹤0.01%	1844

Other funds holding TGTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

KBC Group's TGTX Position: Q1 2026 in Review

KBC Group increased its TG Therapeutics (TGTX) stake by 29% in Q1 2026, buying an estimated $35.6K and bringing the position to 5,335 shares worth $177K. The position accounts for ﹤0.01% of the portfolio, ranked #1022.

KBC Group first reported a position in TGTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $277K in Q1 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

KBC Group held 5,335 shares of TG Therapeutics worth $177K as of Q1 2026.
KBC Group bought 1,195 TG Therapeutics shares in Q1 2026, an estimated $35.6K.
TG Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1022 holding.
KBC Group first reported a position in TG Therapeutics in Q3 2023 and has held it in 11 quarters since.
KBC Group's TG Therapeutics position peaked at $277K in Q1 2025.
363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.